These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10463202)

  • 1. Treatment with the angiotensin II antagonist valsartan in patients with chronic renal failure and hypertension.
    Plum J; Bünten B; Németh R; Grabensee B
    Nephrol Dial Transplant; 1999; 14 Suppl 4():25-7. PubMed ID: 10463202
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of the angiotensin II antagonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension.
    Plum J; Bünten B; Németh R; Grabensee B
    J Am Soc Nephrol; 1998 Dec; 9(12):2223-34. PubMed ID: 9848776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics.
    Epstein M; Hollenberg NK
    Am J Hypertens; 2004 Jul; 17(7):638-9; author reply 639-40. PubMed ID: 15233985
    [No Abstract]   [Full Text] [Related]  

  • 4. Angiotensin II receptor blockers in hypertension and renal disease.
    Bakris GL
    Hosp Pract (1995); 1998 Apr; 33(4):19-22. PubMed ID: 9562828
    [No Abstract]   [Full Text] [Related]  

  • 5. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension.
    Delles C; Klingbeil AU; Schneider MP; Handrock R; Weidinger G; Schmieder RE
    Am J Hypertens; 2003 Dec; 16(12):1030-5. PubMed ID: 14643577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
    Coats AJ
    Int J Cardiol; 2001 Jul; 79(2-3):99-102. PubMed ID: 11461726
    [No Abstract]   [Full Text] [Related]  

  • 7. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease.
    Martin J; Krum H
    Pharmacol Res; 2002 Sep; 46(3):203-12. PubMed ID: 12220962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.
    Hedner T; Oparil S; Rasmussen K; Rapelli A; Gatlin M; Kobi P; Sullivan J; Oddou-Stock P
    Am J Hypertens; 1999 Apr; 12(4 Pt 1):414-7. PubMed ID: 10232502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension.
    Watanabe S; Okura T; Kurata M; Irita J; Manabe S; Miyoshi K; Fukuoka T; Gotoh A; Uchida K; Higaki J
    Clin Exp Hypertens; 2006 Jul; 28(5):451-61. PubMed ID: 16820342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective trials of angiotensin receptor blockers: beyond blood pressure control.
    Siragy HM; Carey RM
    Curr Hypertens Rep; 2000 Apr; 2(2):163-4. PubMed ID: 10981143
    [No Abstract]   [Full Text] [Related]  

  • 11. Valsartan and the kidney: present and future.
    Mann JF
    J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S37-40; discussion S41-3. PubMed ID: 10028953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valsartan: a novel angiotensin type 1 receptor antagonist.
    Thürmann PA
    Expert Opin Pharmacother; 2000 Jan; 1(2):337-50. PubMed ID: 11249553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial in Slovakia.
    Jezek T; Balazovjech I
    Bratisl Lek Listy; 2003; 104(1):19-26. PubMed ID: 12830992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AT1-receptor blockers.
    Petkun W
    Eur Heart J; 2000 Feb; 21(4):335-7. PubMed ID: 10653684
    [No Abstract]   [Full Text] [Related]  

  • 17. Sartans for hypertension--implications of the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
    Cheung BM
    Hong Kong Med J; 2004 Oct; 10(5):359. PubMed ID: 15479968
    [No Abstract]   [Full Text] [Related]  

  • 18. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
    Corea L; Cardoni O; Fogari R; Innocenti P; Porcellati C; Provvidenza M; Meilenbrock S; Sullivan J; Bodin F
    Clin Pharmacol Ther; 1996 Sep; 60(3):341-6. PubMed ID: 8841157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of AT1 receptor blockade on endothelial function in essential hypertension.
    Klingbeil AU; John S; Schneider MP; Jacobi J; Handrock R; Schmieder RE
    Am J Hypertens; 2003 Feb; 16(2):123-8. PubMed ID: 12559678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data].
    Paoletti V; Di Veroli C; Pugliese M; Cammarella I; Cavina G; Turchetti P; Mammarella A
    Clin Ter; 2002; 153(1):61-4. PubMed ID: 11963637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.